Stay updated with breaking news from Biomed res. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
disease in patients at risk of progression with and without type-2 diabetes
of chronic kidney disease in more than 20 years
In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death
AstraZeneca s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.
The approval by the Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year. ....
2Central Tuberculosis Reference Laboratory (CTRL), Dar es Salaam, Tanzania; 3School of Life Science and Bioengineering, Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania; 4University of Saskatchewan, Saskatoon, Canada; 5Department of Epidemiology and Statistics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania Correspondence: Nicholaus P Mnyambwa Email [email protected] Introduction: Antimicrobial resistance is one of the biggest threats of modern public health. Although sub-Saharan Africa is highly burdened with infectious diseases, current data on antimicrobial resistance are sparse. Methods: A prospective study was conducted between October 2018 and September 2019 to assess the antibiotic susceptibility patterns of clinical bacterial isolates obtained from four referral hospitals in Tanzania. We used standard media and Kirby-Bauer disc diffusion methods as per Clinical and Laboratory Standar ....
Visit Novartis Global Health on Twitter and Linkedin. Friday, January 29, 2021 - 1:15am CONTENT: Press Release BASEL, SWITZERLAND, January 29, 2021 /3BL Media/ A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025. Widespread use of MDT has led to a 95% reduction in leprosy prevalence world-wide since its introduction the 1980s, though more than 200,000 cases are still seen every year. 1 Despite the huge impact of MDT, governments, donors, civil society and the private sector will need to collaborate on deploying additional tools if the world is to get to zero leprosy. ....
Smith+Nephew s PICO™ Single Use Negative Pressure Wound Therapy System again shown to significantly reduce surgical site complications News provided by Share this article Share this article LONDON, Jan. 27, 2021 /PRNewswire/ Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, is pleased to announce a new publication showing that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced the odds of surgical site infections (SSIs) by 63% , the odds of seroma by 77% †, and the odds of dehiscence by 30% ‡. A significant benefit of these reduced odds was an almost 2-day reduction in length of stay §, suggesting potential for substantial efficiency gains across the healthcare system ....
22 30% in Harerge, Eastern Ethiopia, 29 27% in Jimma, Southeastern Ethiopia, 30 26.6% in Wolaita Sodo, Southern Ethiopia, 31 31.2% in Hosanna, Southern Ethiopia, 32 and 43% in Brazil. 33 The variation might be due to the variability of time of investigation and sample size among the studies. The prevalence of underweight among participants on ART in Dilla Referral Hospital, Southern Ethiopia was 12.3%, 34 which was lower than the findings of the current study. This might be due to variations in the characteristic of the population. And the magnitude of underweight among patients on ART from this study was higher than the findings 10% in Zimbabwe. 35 The difference might be associated with differences in the population and sample size between the studies. ....